Cavitation-Enhanced Delivery of a Conditionally Replicating Oncolytic Adenovirus by Therapeutic Ultrasound
Cavitation-Enhanced Delivery of a Conditionally Replicating Oncolytic Adenovirus by Therapeutic Ultrasound
25 November 2021
Intellectual property
OxSonics' proprietary IP portfolio
OxSonics’ proprietary intellectual property portfolio consists of multiple patent families and a substantial body of know-how that collectively provide protection to several key elements of the SonoTran® Platform.
Patents protecting OxSonics core technology have been granted across key jurisdictions with several further patents at an advanced stage of prosecution.
